Should You Be on Lisinopril with Moderate-to-Severe ASCVD Plaque and Normal Blood Pressure?
Yes, ACE inhibitors like lisinopril are recommended for patients with atherosclerotic cardiovascular disease (ASCVD) even when blood pressure is normal, as they provide cardiovascular protection beyond blood pressure reduction.
The Evidence for ACE Inhibitors in ASCVD with Normal Blood Pressure
The 2019 ESC Guidelines for Chronic Coronary Syndromes explicitly state that ACE inhibitors (or ARBs) are recommended in the presence of other conditions such as heart failure, hypertension, or diabetes 1. More importantly, the 2006 AHA/ACC Secondary Prevention Guidelines recommend ACE inhibitors for patients with established atherosclerotic vascular disease, including those with coronary disease 2.
The landmark CAMELOT trial directly addressed your question by studying patients with coronary artery disease and normal blood pressure (baseline average 129/78 mmHg). While this trial compared enalapril (another ACE inhibitor) to placebo, enalapril showed a directionally favorable but non-significant reduction in cardiovascular events (20.2% vs 23.1%, HR 0.85, p=0.16) 3. Notably, the calcium channel blocker amlodipine showed stronger benefits in this trial, but ACE inhibitors remain guideline-recommended based on broader evidence.
Why ACE Inhibitors Work Beyond Blood Pressure Control
ACE inhibitors provide pleiotropic cardiovascular benefits that extend beyond their antihypertensive effects:
- Endothelial function improvement: Lisinopril specifically has been shown to improve arterial function in patients with hyperlipidemia, enhancing both endothelium-dependent (acetylcholine response) and endothelium-independent (nitroprusside response) vasodilation 4
- Atherosclerosis stabilization: Studies demonstrate that ACE inhibitors can halt progression and potentially induce regression of atherosclerotic plaque 5
- Insulin resistance mitigation: ACE inhibitors reduce new-onset diabetes and improve outcomes in patients with insulin resistance, which commonly coexists with atherosclerosis 6
- Left ventricular remodeling prevention: Even in normotensive patients, ACE inhibitors reduce adverse cardiac remodeling 7
Practical Implementation
Starting dose: Begin with lisinopril 2.5-5 mg once daily 8, 2
Target dose: Titrate to 20-40 mg daily as tolerated 7, 8
Monitoring considerations:
- Check serum creatinine and potassium within 1-2 weeks of initiation and after dose increases
- Monitor for symptomatic hypotension, though this is less likely with normal baseline blood pressure
- If systolic BP drops below 100 mmHg consistently and causes symptoms, consider dose reduction rather than discontinuation
Critical Caveats
Do not use lisinopril if you have:
- History of angioedema (life-threatening, occurs in <1% but more common in Black patients) 9
- Pregnancy or planning pregnancy 7
- Bilateral renal artery stenosis 7
- Severe renal impairment (eGFR <30 mL/min/1.73 m²) without specialist guidance 10
Common but manageable side effect: Dry cough occurs in up to 10-15% of patients. If troublesome and persistent after rechallenge confirmation, switch to an ARB (angiotensin receptor blocker) like candesartan or valsartan, which provides similar cardiovascular benefits with lower cough risk 9, 1.
The Broader Context: Comprehensive ASCVD Management
While ACE inhibitors are important, they are one component of optimal medical therapy for ASCVD:
- Statin therapy is mandatory: High-intensity statins (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) with LDL-C goal <70 mg/dL, or even <55 mg/dL for very high-risk patients 11, 1, 12
- Antiplatelet therapy: Aspirin 75-100 mg daily unless contraindicated 1, 2
- Consider SGLT2 inhibitors: If you have diabetes or heart failure, these provide additional cardiovascular and mortality benefits 10, 12
- Beta-blockers: Recommended if you have reduced ejection fraction (LVEF ≤40%) or recent MI, but may be reassessed after >1 year if LVEF is preserved 12
Bottom Line
For a patient with moderate-to-severe atherosclerotic plaque and normal blood pressure, lisinopril should be prescribed as part of comprehensive secondary prevention, targeting a dose of 20-40 mg daily. The cardiovascular protection extends beyond blood pressure lowering through improved endothelial function, plaque stabilization, and reduced adverse remodeling. This recommendation is strongest when combined with high-intensity statin therapy, antiplatelet agents, and aggressive risk factor modification including smoking cessation, exercise, and dietary changes 1, 2.